Highlight
– Ramantamig (JNJ-79635322) is a trispecific T-cell engager directed at BCMA, GPRC5D, and CD3 designed to increase tumor binding avidity and overcome antigen-loss mediated resistance in multiple myeloma (MM).
– In preclinical models, ramantamig produced potent cytotoxicity at sub-nanomolar concentrations, depleted malignant plasma cells in patient ex vivo assays and whole-blood co-cultures, and showed tumor prevention and regression activity in murine xenograft models.
– These data support clinical translation; two phase 1 trials in relapsed/refractory MM (NCT05652335, NCT06768489) are ongoing to evaluate safety, tolerability, pharmacokinetics, and early efficacy.
